Literature DB >> 12463270

Epidemiology and economic impact of migraine.

R B Lipton1, W F Stewart, A I Scher.   

Abstract

Migraine is a very common disorder, affecting about 11% of adult populations in Western countries. Prevalence is highest during the peak productive years--between the ages of 25 and 55. The prevalence is higher in females than males at all post-pubertal ages, but the sex ratio varies with age. In the United States, migraine prevalence is higher in those with low income or education, perhaps because migraine interferes with work and school. Most migraineurs mane their headaches without conventional medical advice and generally treat their attacks with over-the-counter medication. The indirect costs of migraine greatly outweigh the cost of treatment, creating opportunities for cost-effective intervention. The public health burden of migraine is substantial due to its high prevalence and prominent temporary disability. The widespread disability produced by migraine is an important target for treatment.

Entities:  

Mesh:

Year:  2001        PMID: 12463270     DOI: 10.1185/0300799039117005

Source DB:  PubMed          Journal:  Curr Med Res Opin        ISSN: 0300-7995            Impact factor:   2.580


  33 in total

Review 1.  Chronic daily headaches in children.

Authors:  Andrew D Hershey; Marielle A Kabbouche; Scott W Powers
Journal:  Curr Pain Headache Rep       Date:  2006-10

Review 2.  Approach to chronic daily headache.

Authors:  Huma U Sheikh
Journal:  Curr Neurol Neurosci Rep       Date:  2015-03       Impact factor: 5.081

3.  The Impact of Post-Traumatic Stress Disorder on the Burden of Migraine: Results From the National Comorbidity Survey-Replication.

Authors:  Aruna S Rao; Ann I Scher; Rebeca V A Vieira; Kathleen R Merikangas; Andrea L Metti; B Lee Peterlin
Journal:  Headache       Date:  2015-10-16       Impact factor: 5.887

4.  The role of the RhoA/ROCK pathway in gender-dependent differences in gastric smooth muscle contraction.

Authors:  Othman Al-Shboul
Journal:  J Physiol Sci       Date:  2015-09-21       Impact factor: 2.781

5.  Adverse reactions related to drugs for headache treatment: clinical impact.

Authors:  Anna Ferrari; Alessandra Ottani; Alfio Bertolini; Arrigo Francesco Giuseppe Cicero; Ciro Pio Rosario Coccia; Sheila Leone; Emilio Sternieri
Journal:  Eur J Clin Pharmacol       Date:  2005-01-19       Impact factor: 2.953

6.  Efficacy and tolerability of zolmitriptan oral tablet in the acute treatment of menstrual migraine.

Authors:  Michael Tuchman; Angela Hee; Ugochi Emeribe; Stephen Silberstein
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

Review 7.  Rizatriptan: a pharmacoeconomic review of its use in the acute treatment of migraine.

Authors:  Paul L McCormack; Rachel H Foster
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

Review 8.  Recent Advances in Pharmacotherapy for Migraine Prevention: From Pathophysiology to New Drugs.

Authors:  Jonathan Jia Yuan Ong; Diana Yi-Ting Wei; Peter J Goadsby
Journal:  Drugs       Date:  2018-03       Impact factor: 9.546

9.  Prophylactic Therapy for Migraine.

Authors:  Shazia Afridi; Holger Kaube
Journal:  Curr Treat Options Neurol       Date:  2003-11       Impact factor: 3.598

10.  The pharmacological management of migraine, part 1: overview and abortive therapy.

Authors:  George Demaagd
Journal:  P T       Date:  2008-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.